Market Research Reports and Industry Reports

TAKEDA , Challenges Ahead for its New European Presiden

  • DESCRIPTION
  • TABLE OF
    CONTENTS
  • RELATED
    REPORTS
  • SAMPLE REQUEST
  • PURCHASE BY
    SECTION
Post Nycomed and Millenium acquisition, the new leadership of non-Japanese CEO/President Mr. Weber will transform Takeda in a truly global Japanese company in the coming years. It is however important to see how he fulfills the Japanese expectation from these acquisitions and fills the gap for Takeda due to the recent failure of its key late stage pipeline candidates (TAK-875, TAK-700 in chemo experienced Prostate Cancer). From its remaining late stage pipeline candidates (Table 2) Vedolizumab, Contrave (Naltoxone + buproprion, obesity) and MLN-9708 (Ph III, Ixazomib, Multiple Myeloma) are important to drive its growth. Of the recent small to mid-sized consolidation activities in 2013 (Table 1), deals done with Natrogen (New-York, Natura alpha, IBD), Resolve therapeutics, and Inviragen demonstrate Takedas focused approach for selective therapy areas (GI Speciality, Autoimmune, Vaccines), while its deal with Arbor for out licensing EDARBI US rights reveals its decreasing focus on primary care therapy area for global market.Vortioxetine (Brintellix) US launch for MDD Likely in Early 2014 Competitive Enough Against Genericized MDD Market, Edivoxetine failure a moderate Positive- while development of Brexpiprazole looks a close competitor!.........Vedolizumab (MLN0002, UR, US/EU, vedolizumab, 47 integrin inhibitor, Ulcerative colitis / Crohns disease) and MLN-9708 (PhIII, Multiple Myeloma) are the most promising late stage two key candidates: Vedolizumab approval in 2014 in UC/CD by mid 2014 is key to watch out for-MLN-9708/Velcade- Our View on Takedas Multiple Myeloma franchise-TAK-700 - Unable to demonstrate OS benefit in chemo experienced patients- What to expect in chemo nave pool and in earlier setting?- This 30 page detailed report on Takeda pharmaceuticals provide insightful analysis on its recent M & A activities and potential of late stage pipeline candidates based on their global competitive landscape
Table 1 : DEALS DONE BY TAKEDA IN 2013
- Table 2 : KEY LATE STAGE PIPELINE CANDIDATES- TAKEDA
- Table 3 : Vortioxetine - MAJOR DEPRESSIVE DISORDER - LATE STAGE PIPELINE
-Table 4 : MAJOR DEPRESSIVE DISORDER - EARLY STAGE PIPELINE
- Table 5 : VORTIOXETINE- MAJOR DEPRESSIVE DISORDER - DRUGS
DISCONTINUED IN THE RECENT PAST
- Table 6: Vortioxetine - MAJOR DEPRESSIVE DISORDER COMPETITIVE LANDSCAPE
-Table 7 : PIPELINE LEUKOCYTE TRAFFIC INHIBITOR (INTEGRIN INHIBITOR)
- Table 8 : COMPETITIVE LANDSCAPE
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN ULCERATIVE COLITIS
- TAble 9 : Takeda Competitive Landscape
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN CROHNS
DISEASE
- Table 10 : Takeda MLN 0002/Vedolizumab Clinical trial Programme
- Table 11 : MLN9708 - DATA COMPARISON - NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
- Table 12 : DATA COMPARISON - RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
- TAble 13 : COMPARISON OF CY17 INHIBITORS PIPELINE DRUGS ACTING ON
ANDROGEN SYNTHESIS
- Table 14: TAK-700 - KEY CANDIDATES OF ANTI ANDROGEN THERAPY IN PC
- Table 15: Key Milestones of Takeda

List Of Tables

Chart 1 Anti-Depressants WW Competitive Landscape
- chart 2 : MLN9708 -Trial design of TOURMALINE-MM1 RRMM
- chart 3 : REPORTED ADVERSE EVENTS IN CLINICAL TRIALS -MLN9708
-Chart 4: TAK-700 - DRUGS ACTING THROUGH ANDROGEN PATHWAY IN PC
-Chart 5: Nesina US Prescription trend

List Of Figures

Table 1 : DEALS DONE BY TAKEDA IN 2013
- Table 2 : KEY LATE STAGE PIPELINE CANDIDATES- TAKEDA
- Table 3 : Vortioxetine - MAJOR DEPRESSIVE DISORDER - LATE STAGE PIPELINE
-Table 4 : MAJOR DEPRESSIVE DISORDER - EARLY STAGE PIPELINE
- Table 5 : VORTIOXETINE- MAJOR DEPRESSIVE DISORDER - DRUGS
DISCONTINUED IN THE RECENT PAST
- Table 6: Vortioxetine - MAJOR DEPRESSIVE DISORDER COMPETITIVE LANDSCAPE
-Table 7 : PIPELINE LEUKOCYTE TRAFFIC INHIBITOR (INTEGRIN INHIBITOR)
- Table 8 : COMPETITIVE LANDSCAPE
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN ULCERATIVE COLITIS
- TAble 9 : Takeda Competitive Landscape
MLN 0002/VEDOLIZUMAB VS. MARKETED MAB IN CROHNS
DISEASE
- Table 10 : Takeda MLN 0002/Vedolizumab Clinical trial Programme
- Table 11 : MLN9708 - DATA COMPARISON - NEWLY DIAGNOSED MULTIPLE MYELOMA (NDMM)
- Table 12 : DATA COMPARISON - RELAPSED AND REFRACTORY MULTIPLE MYELOMA (RRMM)
- TAble 13 : COMPARISON OF CY17 INHIBITORS PIPELINE DRUGS ACTING ON
ANDROGEN SYNTHESIS
- Table 14: TAK-700 - KEY CANDIDATES OF ANTI ANDROGEN THERAPY IN PC
- Table 15: Key Milestones of Takeda

Takeda Pharmaceutical Company Limited - Strategy, SWOT and Corporate Finance Report

Takeda Pharmaceutical Company Limited - Strategy, SWOT and Corporate Finance Report, is a source of comprehensive company data and information. The report covers the companys structure, operation, SWOT analysis, product

USD 175View Report

Takeda Cambridge Limited - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Takeda Cambridge Limited (TCB), formerly Paradigm Therapeutics Limited, a subsidiary of Takeda Pharmaceutical Company Limited, pharmaceutical company that develops novel compounds addressing in various therapeutics areas. The company specializes in

USD 250View Report

Takeda Pharmaceuticals International AG - Pharmaceuticals & Healthcare - Deals and Alliances Profile

Takeda Pharmaceuticals International AG (Takeda), a subsidiary of Takeda Pharmaceutical Company Limited is a pharmaceutical company that offers researches, development, manufacturing and marketing of pharmaceutical products. The company offers treatments

USD 250View Report

The Connected Car Ecosystem: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts

The growing proliferation of embedded in-vehicle connectivity and smartphone integration platforms has made connected cars one of the fastest growing segments of the IoT (Internet of Things) market. Keen to

USD 2500View Report

The Mobile Phone Insurance Ecosystem: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts

Given the increasing prevalence of expensive household goods, cars and consumer electronics, insurance has become an unavoidable and often necessary cost in modern life. Mobile phones, and smartphones in particular

USD 2500View Report

The SON (Self-Organizing Networks) Ecosystem: 2016 – 2030 – Opportunities, Challenges, Strategies & Forecasts

SON (Self-Organizing Network) technology minimizes the lifecycle cost of running a mobile network by eliminating manual configuration of equipment at the time of deployment, right through to dynamically optimizing performance

USD 2500View Report

Fill The Form For Sample Request
Name*
Email*
Mobile No.*
LandLine No.
If you want to purchase particular section from this report then kindly contact us at contact@aarkstore.com.

Delivery Details

PDF FORMAT REPORTS will be delivered by email within 12 to 24 hours after placing the order (Mon-Fri IST)

CHOOSE FORMAT

  • PDF    $ 500
  • Site Licence    $ 1000
  • Enterprisewide Licence    $ 1500
$ 500

Reports Details

Published Date : Jan 2013
No. of Pages :24
Country :Global
Category :Healthcare
Publisher :MP Advisors
Report Delivery By :Email
Report Delivery Time :12 to 24 hours after placing the order.

Customized Research

If you do not find this specific report suitable to your exact needs then you can also opt for customized research report that will befit all your expectation. To specify your requirements CLICK HERE

 

We Accept

payment